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Abstract   30 
The cytokine erythropoietin (EPO) is the master regulator of erythropoiesis. 31 
Intriguingly, many studies have shown that the cognitive performance of patients 32 
receiving EPO for its hematopoietic effects is enhanced, which prompted the growing 33 
interest in the use of EPO-based strategies to treat neuropsychiatric disorders. EPO 34 
plays key roles in brain development and maturation, but also modulates synaptic 35 
transmission. However, the mechanisms underlying the latter have remained elusive. 36 
Here, we show that acute (40-60 min) exposure to EPO presynaptically downregulates 37 
spontaneous and afferent-evoked excitatory transmission, without affecting basal firing 38 
of action potentials. Conversely, prolonged (3h) exposure to EPO, if followed by a 39 
recovery period (1h), is able to elicit a homeostatic increase in excitatory spontaneous, 40 
but not in evoked, synaptic transmission. These data lend support to the emerging view 41 
that segregated pathways underlie spontaneous and evoked neurotransmitter release. 42 
Furthermore, we show that prolonged exposure to EPO facilitates a form of 43 
hippocampal long-term potentiation (LTP) that requires non-canonical recruitment of 44 
calcium-permeable AMPA receptors (CP-AMPARs) for its maintenance. These 45 
findings provide important new insight into the mechanisms by which EPO enhances 46 




Keywords: Erythropoietin; hippocampus; homeostatic plasticity; long-term 51 




Erythropoietin (EPO) is a pleiotropic hormone from the type I cytokine super-family 54 
best known as a crucial regulator of erythropoiesis and tissue oxygenation homeostasis. 55 
In addition, EPO signaling has been shown to play key roles in the central nervous 56 
system (CNS), where neurons and astrocytes express a specific non-hematopoietic EPO 57 
receptor (Fond et al., 2012). EPO is an important regulator of neuronal proliferation 58 
and migration during CNS development and also following injury to the mature brain, 59 
such as during post-stroke recovery (Tsai et al., 2006). Intriguingly, in addition to its 60 
role in neurogenesis, early studies reported positive cognitive effects in patients 61 
regularly receiving EPO for chronic kidney disease (Kambova, 1998; Pickett et al., 62 
1999). Similar pro-cognitive effects have since been reported in patients with 63 
schizophrenia (Ehrenreich et al., 2007), bipolar disorder (Miskowiak et al., 2014) and 64 
type 1 diabetes (Kristensen et al., 2013). 65 
These cognitive-enhancing effects might be partially explained by the fact that EPO 66 
raises hemoglobin levels and improves brain oxygenation or could reflect the anti-67 
apoptotic, anti-oxidative and anti-inflammatory properties of this cytokine (Brines and 68 
Cerami, 2005; Sirén, 2009; Fond et al., 2012). However, treatment with EPO has been 69 
shown to amplify the expression of pro-plasticity genes in an experimental stroke model 70 
at early time points, even before EPO would be expected to reduce inflammation or 71 
neuronal apoptosis (Mengozzi et al., 2012).  72 
In keeping with these data, recent evidence indicates that EPO directly modulates 73 
neuronal activity and plasticity (Adamcio et al., 2008; Kamal et al., 2011; Sargin et 74 
al., 2011). However, differences in the experimental models used to investigate EPO 75 
signaling have yielded some inconsistencies in results (Supplementary Table 1). We 76 
propose that, at least partially, this is due to the fact that differences in effect between 77 
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acute neuronal tuning vs. network effects of prolonged exposure have not been 78 
accounted for.  79 
Here, we directly compared the effects of acute EPO application (aEPO) with those of a 80 
more prolonged exposure (pEPO) using ex vivo and in vitro experimental models that 81 
isolate the actions of EPO to the neuronal/astrocytic compartment. Our results 82 
demonstrate that acute EPO acts as an inhibitor of synaptic transmission, 83 
downregulating excitatory and upregulating inhibitory spontaneous activity. In contrast, 84 
more prolonged exposure (3h) to EPO, followed by a recovery period (1h), resulted in 85 
opposite, homeostatic changes in spontaneous synaptic transmission. These results 86 
resemble those observed following exposure to an activity deprivation (AD) paradigm 87 
with tetrodotoxin (TTX, 1 μM), a sodium channel blocker, and APV (50 μM), a N-88 
methyl-D-aspartate receptor (NMDAR) antagonist (Sutton et al., 2006; Félix-Oliveira 89 
et al., 2014). Therefore, in order to better understand the consequences of EPO’s 90 
homeostatic actions, we directly compared the effects of prolonged EPO against those 91 
of the AD protocol on network excitability and hebbian synaptic potentiation. 92 
  93 
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Materials and Methods 94 
 95 
Animals 96 
All experiments were conducted using Wistar or Sprague-Dawley rats, as indicated. 97 
Animals were kept under standardized temperature, humidity and lighting conditions, 98 
with access to water and food ad libitum. All animal procedures were carried out 99 
according to the Portuguese law and the European Community Guidelines for Animal 100 
Care (European Union Council Directive – 2010/63/ EU). Throughout the underlying 101 
experimental work, care was taken to minimize the number of animals sacrificed. 102 
 103 
Primary Hippocampal Cultures  104 
Pregnant Sprague-Dawley rats were obtained from Harlan Interfauna Iberia (Barcelona, 105 
Spain). Animals were deeply anesthetized with halothane (2-Bromo-2-Chloro-106 
1,1,1Trifluoroethane) in an anesthesia chamber before being sacrificed by decapitation. 107 
Briefly, embryos (E17-E18) were rapidly removed from the uterus, their brains removed 108 
and placed in cold Ca2+- and Mg2+-free Hank’s Balanced Salt Solution supplemented 109 
with 0.37% glucose (HBSS-glucose). After brain isolation, meninges were gently 110 
removed from the hemispheres. All hippocampi were collected in fresh HBSS-glucose 111 
and trypsinization was carried out (0,350 ml of 2,5% trypsin) at 37 ºC for 15 min in a 112 
water bath. Afterwards, trypsin solution was gently removed and 30% Fetal Bovine 113 
Serum (FBS) in HBSS-glucose was added and let stand for 5 min at room temperature 114 
(RT, 22-24ºC) to quench trypsin activity. The pellet was resuspended in Neurobasal 115 
medium (Neurobasal-B27: Neurobasal supplemented with 0.5 mM glutamine, 2% B27, 116 
25 U/mL penicillin/streptomycin) and 25 mM glutamic acid. Cell suspension was 117 
filtered using a nylon filter (Cell Strainer 70 µM, BD FalconTM) and cell density was 118 
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determined by counting cells in a 0.4% trypan blue solution using a hemacytometer. 119 
Cells were plated at 4x104 cells/cm2 in 24-well plates with glass coverslips (Marienfeld, 120 
Germany) coated with poly-D-lysine (PDL, 50 µg/ml). The cultures were maintained 121 
for a maximum of 21 days, in an incubator with a humidified 37ºC and 5% CO2 122 
atmosphere with no media exchange. 123 
 124 
Acute Slice preparation and incubation 125 
Young Wistar rats (3-5 weeks old) were killed by decapitation under deep isoflurane 126 
anesthesia. The brain was quickly removed, hemisected and both hippocampi were 127 
dissected free within ice-cold dissecting solution containing (in mM): 110 sucrose; 2.5 128 
KCl; 0.5 CaCl2; 7 MgCl2; 25 NaHCO3; 1.25 NaH2PO4; and 7 glucose; previously 129 
gassed with 95% O2 and 5% CO2, pH 7.4.  130 
For extracellular recordings, slices (350 μm-thick) were cut perpendicularly to the long 131 
axis of the hippocampus with a McIlwain tissue chopper (unless stated otherwise) and 132 
allowed to recover functionally and energetically for at least 60 min at RT, in a resting 133 
chamber filled with artificial cerebrospinal fluid (aCSF) (containing, in mM: 124 NaCl; 134 
3 KCl; 1.25 NaH2PO4; 26 NaHCO3; 1 MgSO4; 2 CaCl2; and 10 glucose), previously 135 
gassed with 95% O2 and 5% CO2, pH 7.4.  136 
For patch-clamp recordings, acute hippocampal (300 μm-thick) slices were cut using a 137 
vibratome (VT1000 S; Leica, Nussloch, Germany) in the aforementioned ice-cold 138 
dissecting solution. Slices were first incubated for 30 min at 35°C in gassed aCSF 139 
followed by at least 60 min of recovery at RT.   140 
Hippocampal slices were incubated with vehicle, with EPO (2.4 IU/ml) alone, with both 141 
TTX (1 μM) and AP-V (50 μM) or with these three drugs simultaneously, for 3 hours, 142 
at RT, in gassed aCSF. For some experimental designs, this was followed by a 143 
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washout/recovery period of 1 hour in gassed aCSF at RT, as indicated. EPO 144 
concentration (2.4 IU/ml) corresponds to a concentration 8-times (23) higher than that 145 
used by others in cultured cells (Adamcio et al., 2008). This was done since it is more 146 
difficult for EPO to permeate hippocampal slices (300-350 µm-thick), than cultured 147 
cells (in monolayer). 148 
 149 
Electrophysiology 150 
Extracellular ex vivo Recordings.  151 
Slices were transferred to a submerging chamber (1 ml) and continuously superfused at 152 
a 3 ml/min rate with gassed aCSF at 32ºC. Evoked orthodromic field excitatory 153 
postsynaptic potentials (fEPSP) were recorded extracellularly through a microelectrode 154 
filled with 4 M NaCl (2–8 MΩ resistance) placed in the stratum radiatum of the CA1 155 
area, as previously described (see e.g. Rodrigues et al., 2014). One pathway of the 156 
Schaffer collateral (SC)/commissural fibers was stimulated (rectangular pulses of 0.1 157 
ms duration) at every 15 s (for I/O curves, basal synaptic transmission and PPF 158 
recordings) or every 20 s (for LTP recordings), by a bipolar concentric wire electrode 159 
placed on the Schaffer fibers in the stratum radiatum, in the CA1 area. The initial 160 
intensity of the stimulus was adjusted to obtain a submaximal fEPSP slope with a 161 
minimum population spike contamination, near one-fourth of the fEPSP slope obtained 162 
with supramaximal stimulation. The averages of eight (for I/O curves, basal synaptic 163 
transmission and PPF recordings) or six consecutive fEPSP (for synaptic plasticity 164 
recordings) were obtained and the slope of the initial phase of the potential was 165 
quantified. Recordings were obtained with an Axoclamp 2B amplifier (Axon 166 
Instruments, Foster City, CA), digitized and continuously stored on a personal computer 167 
with the LTP program (Anderson and Collingridge, 2001). All the protocols detailed 168 
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below were started only after a stable baseline of at least 20 minutes. In the tracings 169 
shown, the stimulus artifact was truncated for clarity. 170 
Basal Synaptic Transmission. Alterations in synaptic transmission induced by EPO (2.4 171 
IU/ml) were evaluated as % change in the average slope of the fEPSP 50-60 min after 172 
EPO application, relatively to the average slope of the fEPSP measured during the 10 173 
min that preceded addition of EPO to the superfusing solution.  174 
Paired-Pulse Facilitation (PPF) Recordings. PPF was quantified as the percentage of 175 
slope facilitation between two consecutive fEPSPs (fEPSP2/fEPSP1) elicited with a 50-176 
ms interstimulus interval. PPFs were continuously elicited for 60 min; EPO was added 177 
to the superfusing solution 20 min after having started the PPF protocol. Alterations in 178 
PPF efficiency induced by EPO (2.4 IU/ml) were evaluated as % change in the average 179 
PPF ratio 30-40 min after EPO application, relatively to the average PPF ratio measured 180 
during the 10 min that preceded the addition of EPO to the superfusing solution. As a 181 
control, in different slices, PPFs were continuously elicited for 60 min, adding only 182 
vehicle to the superfusing solution, to test whether continuously eliciting PPFs for that 183 
time period would per se change PPF efficiency.  184 
Input/Output Curves. The stimulus delivered to the slice was decreased until no fEPSP 185 
was evoked and subsequently increased in 20 μA steps. Data from three consecutive 186 
averages of eight fEPSPs were collected for each stimulation intensity. Inputs delivered 187 
to slices typically ranged from 80 μA to a supramaximal stimulation of 320 μA. fEPSP 188 
slope was plotted as a function of stimulus intensity. The maximum slope values were 189 
obtained by extrapolation upon nonlinear fitting of the I/O curve and an F test was used 190 
to determine differences between the parameters. Whenever the stimulus was intense 191 
enough to elicit a population spike (depolarization that follows the fEPSP), its 192 
amplitude was measured. Each popspike amplitude replicate was plotted as a function 193 
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of the slope of the associated fEPSP and the popspike/fEPSP ratio calculated as the 194 
quotient between these values. 195 
LTP induction. A weak LTP-inducing θ-burst protocol consisting of four trains of 100 196 
Hz, four stimuli, separated by 200 ms was used (1x4x4). The intensity of the stimulus 197 
was never changed throughout the experiment. LTP magnitude was quantified as the % 198 
change in the average of the fEPSP taken from 50 to 60 min after LTP induction 199 
relative to the average slope of the fEPSP measured during the 10 min that preceded 200 
induction of LTP. Post-tetanic potentiation (PTP) was assessed as the average fEPSP 201 
slope obtained in the first 8 min after LTP induction (Habets and Borst, 2007).  202 
For the experiments in Figure 7, stimulation was delivered, every 10 s, alternatively to 203 
two independent pathways of the Schaffer collateral/commissural fibers. In each 204 
individual experiment, the LTP-inducing paradigm was delivered to one of the 205 
pathways and, 1 hour thereafter, to the other pathway; each pathway was used as control 206 
or test in alternate days. NASPM (20 μM) was added to the superfusing solution 20 min 207 
after the induction of the 2nd LTP. This protocol allowed to test the effect of NASPM on 208 
LTP maintenance, with the first LTP serving as an internal control. The LTP inducing 209 
protocol used was the same and LTP magnitude was quantified as explained above. 210 
Antidromic Population Spike (Popspike) Recordings. Hippocampal slices used were 211 
prepared as described above for patch-clamp recordings. Evoked antidromic popspikes 212 
were recorded extracellularly through a microelectrode filled with 4 M NaCl (2–8 MΩ 213 
resistance) placed in CA1 pyramidal cell layer. Antidromic responses were evoked by 214 
stimulation in the alveus, every 15 s, by a bipolar concentric wire electrode (Kabakov 215 
et al., 2012). The initial intensity of the stimulus was adjusted to obtain a submaximal 216 
popspike amplitude with minimal contamination. Averages of eight responses were 217 
obtained and the popspike amplitude was calculated as the amplitude from the popspike 218 
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peak to the intersection with an interpolated tangent line drawn between the pre-219 
popspike peak and the post-popspike peak (Figure S1A). Recordings were obtained 220 
with an Axoclamp 2B amplifier (Axon Instruments, Foster City, CA), digitized and 221 
continuously stored on a personal computer with the LTP program (Anderson and 222 
Collingridge, 2001). In order to demonstrate that nonsynaptic excitatory transmission 223 
underlies the popspikes we recorded, control experiments were performed (for a 224 
representative experiment, see Figure S1B). Alterations in popspike amplitude induced 225 
by EPO (2.4 IU/ml) were evaluated as % change in the average amplitude of the 226 
popspike 50-60 min after EPO application, relatively to the average amplitude of the 227 
popspike measured during the 10 min that preceded addition of EPO to the superfusing 228 
solution.  229 
 230 
Patch-clamp Recordings. 231 
Whole cell patch-clamp recordings were obtained either from hippocampal CA1 232 
pyramidal cells or from hippocampal cultured neurons, as indicated. These were 233 
visualized with an upright microscope (Zeiss Axioskop 2FS) equipped with infrared 234 
video microscopy and differential interference contrast optics. Recordings were 235 
performed at RT in current-clamp or voltage-clamp mode with an Axopatch 200B 236 
(Axon Instruments) ampliﬁer. For current-clamp recordings and for miniature or 237 
spontaneous excitatory postsynaptic current (mEPSC or sEPSC, respectively) 238 
recordings, patch pipettes (4- to 7-MΩ resistance) were ﬁlled with an internal solution 239 
containing (in mM): 125 K-gluconate, 11 KCl, 0.1 CaCl2, 2 MgCl2, 1 EGTA, 10 240 
HEPES, 2 MgATP, 0.3 NaGTP, and 10 phosphocreatine, pH 7.3, adjusted with 1 M 241 
KOH, 280–290 mOsm. For miniature inhibitory postsynaptic current (mIPSC) 242 
recordings and AMPA- and NMDA-mediated responses, the internal solution contained 243 
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(in mM): 125 CsCl, 8 NaCl, 1 CaCl2, 10 EGTA, 10 HEPES, 10 glucose, 5 MgATP, and 244 
0.4 NaGTP, pH 7.2, adjusted with CsOH (50 wt% in H2O), 280–290 mOsm. Acquired 245 
signals were ﬁltered using an in-built, 2-kHz, three-pole Bessel ﬁlter, and data were 246 
digitized at 5 or 10 kHz under control of the pCLAMP 10 (Molecular Devices) software 247 
program. The junction potential was not compensated for, and offset potentials were 248 
nulled before giga-seal formation. Small voltage steps (–5 mV, 50 ms) were used to 249 
monitor the access resistance throughout experiments. The holding current was also 250 
constantly monitored and experiments in which any of these parameters varied by more 251 
than 20% were discarded.  252 
Current-clamp recordings. The resting membrane potential was measured immediately 253 
upon establishing whole cell conﬁguration. Changes in membrane potential and action 254 
potentials were evoked under current-clamp mode by injection of 500 ms current pulses 255 
(25 to 275 pA in 25 pA increments) from an initial holding potential (Vh) of –70 mV. 256 
The threshold for action potential (AP) generation was determined as the difference 257 
between the resting membrane potential (Vm) and the membrane potential at which 258 
phase plot slope reached 10 mV/ms (Vt) (Naundorf et al., 2005). When studying the 259 
effect of acute EPO/vehicle superfusion upon spiking frequency, neurons were initially 260 
current-clamped to –60 mV (the closest to our sample average resting membrane 261 
potential) and this holding current was kept constant throughout the experiment. After 262 
10 min of baseline recording, EPO (2.4 IU/ml) or vehicle were added to the superfusion 263 
solution and membrane potential variations were recorded for at least 40 min. The 264 
average spiking frequency was calculated as the frequency of APs within the entire 265 
period of superfusion with EPO/vehicle.  266 
Spontaneous activity. Spontaneous mEPSCs were recorded in aCSF supplemented with 267 
TTX (500 nM) and gabazine (2 μM). Spontaneous mIPSCs were recorded in aCSF 268 
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supplemented with TTX (500 nM) and kynurenic acid (1 mM). For sEPSC recordings 269 
only gabazine (2 μM) was added to perfusion. Analysis of spontaneous events was 270 
performed using the Synaptosoft Mini Analysis Program software with the amplitude 271 
threshold for event detection set at 3x the average root-mean-square noise. 272 
Synaptic Failure Rate. These experiments were performed using minimum stimulation. 273 
Recordings were performed in the continuous presence of picrotoxin (100 µM). 274 
Synaptic responses were obtained with a bipolar electrode placed over Schaffer 275 
collateral fibers and stimuli (100 µs) were delivered every 5 s. AMPA-mediated 276 
responses were measured as the peak amplitude value of the EPSC at –60 mV and 277 
NMDA-mediated responses as the peak amplitude value of the EPSC at +40 mV, at a 278 
latency where AMPA responses had fully decayed (30-60 ms) (Arendt et al., 2013). 279 
The criterion used for defining success of synaptic transmission was peak amplitude 280 
values greater than 20 pA for AMPA-mediated responses and 10 pA for NMDA-281 
mediated responses. Failure rate was calculated as a percentage of failed evoked 282 
responses over 50 sweeps. In the amplitude scatter plots, for ease of visualization, the 283 
amplitudes of failure trials were plotted as zero. To facilitate the interpretation of the 284 
tracings shown, the stimulus artifact was blanked. 285 
 286 
Live Imaging of SEP-GluA2 287 
Live imaging experiments were performed using primary cultured hippocampal neurons 288 
at DIC 17-24, prepared as routinely in the lab (Martin and Henley, 2004), 12h-24h 289 
upon infection with Sindbis virus carrying Super Ecliptic Phluorin-GluA2 (SEP-GluA2) 290 
(Ashby et al., 2004; 2006). Neurons were placed on a heated stage (set at 35ºC) of a 291 
Nikon TE-2000E inverted microscope (Garden City, NY) and were continually perfused 292 
at 3 ml/min with warm Earle’s solution containing either TTX (500 nM) alone for the 293 
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baseline and washout period or TTX (500 nM) and EPO (2.4 IU/mL) during the test 294 
period. Low pH external solutions contained equimolar MES instead of HEPES (pH 295 
adjusted to 6). NH4Cl (50 mM) was used in place of equimolar NaCl to collapse pH 296 
gradients. Fluorescence was excited using a 63x water-immersion objective by a 488 297 
nm laser light and emission was detected through a 505 nm long pass filter. Time series 298 
were collected as repetitively scanned images. All SEP-GluA2 experiments included a 299 
brief (30 sec) low pH wash at the end of each experiment, to subtract the remaining 300 
signal (internal AMPAR fluorescence) from the total and thus obtain the signal 301 
corresponding to surface-expressed AMPARs. 302 
 303 
Immunocytochemistry and Confocal Microscopy 304 
DIC 15 and DIC 21 hippocampal neurons were washed with Phosphate Buffered Saline 305 
(PBS) (containing in mM: 137 NaCl, 2.1 KCl, 1.8 KH2PO4, 10 Na2HPO4.2H2O, pH 306 
7.40), containing sucrose whenever needed to correct the solution to the medium 307 
osmolarity. Cells were then fixed with 4% phosphate buffered paraformaldehyde (PFA) 308 
at RT, for 20 minutes. Excess of PFA was removed by washing with PBS solution. 309 
Cells were permeabilized and blocked for 1h using PBS containing 1% bovine serum 310 
albumin (BSA, Sigma-Aldrich) and 0.1% Tween 20, at RT, and, then, incubated for 1 311 
hour, at RT, with a mouse monoclonal primary antibody anti-MAP2 (1:200) and a 312 
rabbit polyclonal primary antibody anti-EpoR (1:200; dilution range typically used 313 
varies from 1:100 to 1:500, Bernaudin et al., 1999; Sanchez et al., 2009), in blocking 314 
solution. Washes to remove the excess of primary antibody were then performed in 315 
PBS. Hippocampal cultured neurons were subsequently incubated for 2 hours, at RT, 316 
with a donkey anti-mouse and donkey anti-rabbit secondary antibodies respectively 317 
conjugated to the fluorescent label Alexa Fluor 568 (1:500) and 488 (1:250) in blocking 318 
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solution. Images of neurons were captured using a confocal point-scanning microscope 319 
(Zeiss LSM 710, Germany) with a 63x objective and using the software ZEN 2009 320 
(Carl Zeiss MicroImaging). The pixel size in the object space was 0.13 μm and the 321 
captured images were 1024 x 1024 pixels size. Images were stored and analyzed in an 322 
uncompressed 16-bit .tiff format. 323 
As a quality control of the anti-EpoR antibody, a blocking peptide competition assay 324 
was also performed (Figure S2). In this case, DIC 15 hippocampal neurons were either 325 
incubated with the primary antibody or with the primary antibody after being pre-326 
incubated with the blocking peptide in a proportion of either 1:5 or 1:10 (primary 327 
antibody:blocking peptide) (Brownjohn and Ashton 2014). 328 
EpoR protein intensity quantification. Hippocampal neuronal images with a 16-bit .tiff 329 
format were analyzed by using ImageJ (1.46r, NIH) software. EpoR expression in the 330 
soma and dendrites was evaluated by quantifying respectively the mean gray value of 331 
the soma and the mean gray value of the dendrites (by definition, the mean gray value 332 
corresponds to the sum of the gray values of all pixels in the selected area divided by 333 
the number of pixels). First, the threshold of the whole neuronal area was adjusted on 334 
the MAP2 channel, being this region selected as the region of interest (ROI) for the 335 
neuron (A). The cell body was selected by drawing a polygon (B) and the whole image 336 
was also selected (C). These three ROIs were then combined in order to limit the areas 337 
to the cell body (A∩B), the dendrites (A\B) and the background (C\A). By measuring, 338 
the program gave the mean gray values of the EpoR channel for the three combined 339 
ROIs plus the background. Then, the background mean gray value was subtracted from 340 




EPO was purchased from Jena Bioscience (Jena, Germany) and was prepared in 343 
distilled water with 0.1% BSA as 100 µg/mL stock solution. TTX (tetrodotoxin citrate), 344 
gabazine, DL-APV (DL-2-amino-5-phosphonopentanoic acid), kynurenic acid and 345 
CNQX (6-Cyano-7-nitroquinoxaline-2,3-dione) were all purchased from Abcam 346 
Biochemicals (Cambridge, MA, USA) and were prepared in distilled water as 1, 10, 50, 347 
100 and 10 mM stock solutions, respectively. Picrotoxin was also purchased from 348 
Abcam Biochemicals (Cambridge, MA, USA) and prepared in dimethylsulfoxide 349 
(DMSO) as a 50 mM stock solution. K252a was purchased from Tocris Cookson 350 
(Ballwin, MO, USA) and made up in a 1 mM stock solution in DMSO. NASPM (1-351 
naphthylacetylspermine) was purchased from Sigma-Aldrich (St. Louis, MO, USA) and 352 
prepared as 10 mM stock solution in distilled water. For the live imaging assays, EPO, 353 
TTX and APV from the same batches as those used for the electrophysiology 354 
experiments were used.  For the immunocytochemistry procedures, to identify EpoR, a 355 
polyclonal rabbit antibody [Santa-Cruz Biotechnology, No. sc-697 (M-20), stock 356 
concentration 200 µg/mL] raised against amino acids 488-507, mapping at the C-357 
terminal cytoplasmic domain (amino acids 273-507) of the precursor form of mouse 358 
EpoR, was used. As dendritic marker, we used a mouse anti-MAP2 monoclonal 359 
antibody (Chemicon, Millipore, No. MAB3418, stock concentration 1 mg/mL). The 360 
reagents used for primary hippocampal cultures were purchased from Invitrogen 361 








All data were tested for normality with Kolmogorov-Smirnov test. Data presented as 368 
mean ± s.e.m have normal distributions and t-test or one-way ANOVA were used to test 369 
for significance. Otherwise, data were shown as median and quartiles and Mann-370 





EPO acutely (aEPO) downregulates evoked transmission by operating presynaptic 374 
mechanisms 375 
We first reexamined the effect of acute EPO (aEPO) superfusion on afferent-evoked 376 
transmission to CA1 neurons, by eliciting orthodromic fEPSPs in hippocampal slices. 377 
We found that aEPO significantly inhibited fEPSP slope (Figure 1B1) even when 378 
applied at a lower, more physiological concentration (2.4 IU/ml) than previously used 379 
(50 IU/ml in Kamal et al., 2011). EPO signals through EPO receptors (EpoRs), which 380 
are frequently found as homodimeric tyrosine kinase receptors (RTKs) in the CNS 381 
(Digicaylioglu and Lipton, 2001; Ma et al., 2016). As shown in Figure 1B2-C, the 382 
effect of EPO was prevented by the tyrosine kinase inhibitor, k252a (200 nM), thus 383 
suggesting that EPO downregulates afferent-evoked transmission at SC-CA1 synapses 384 
through homodimeric EpoRs. Interestingly, we found a consistent time lag of 385 
approximately 10 minutes before aEPO’s effect became apparent (Figure 1B1). This 386 
lag was described before by Kamal et al., 2011 and may relate to the fact that none of 387 
the known signaling molecules downstream to the EpoR are able to directly modulate 388 
membrane ionic currents (Ma et al., 2016); thus, additional steps (e.g., ion channel 389 
membrane trafficking or degradation) may be required.   390 
In order to further dissect the effect of acutely applied EPO on activity-dependent 391 
synaptic transmission, namely to determine whether it should be ascribed to pre- and/or 392 
postsynaptic mechanisms, we performed a paired-pulse facilitation (PPF) protocol, 393 
evoked antidromic responses from CA1 neurons and recorded spontaneous changes in 394 
membrane potential intracellularly from CA1 pyramidal cells (PCs) soma. We found 395 
that (1) the paired-pulse facilitation (PPF) ratio was significantly increased after aEPO 396 
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(40 min, 2.4 IU/ml) perfusion (n=5, p=0.0019, paired t-test; Figure 1D), which 397 
indicates that EPO reduced the probability of excitatory neurotransmitter release; (2) the 398 
popspike amplitude of antidromically-evoked responses was unaffected by aEPO (60 399 
min, 2.4 IU/ml; n=5-6, p=0.8409, unpaired t-test; Figure 1E-F), which suggests that 400 
EPO has no effect on non-synaptically driven excitatory activity of postsynaptic PCs; 401 
and (3) the frequency of spontaneous action potentials (AP) recorded from the soma of 402 
CA1 PCs, current-clamped to a near-resting membrane potential of –60 mV, was not 403 
affected by aEPO (40 min, 2.4 IU/ml) [vehicle: 0.56 (0.26-1.58) Hz; EPO: 0.59 (0.01-404 
1.55) Hz; n= 6-9, p=0.7756, Mann-Whitney test; data represented as median 405 
(interquartile range); Figure 1G-H]. Taken together, these data suggest that acute 406 
EPO’s effect on neuronal transmission is inherently synaptic and that EPO should 407 
mainly operate through presynaptic mechanisms to inhibit transmission at SC-CA1 408 
synapses. 409 
Consistent with these results, live-imaging assays of GFP-tagged postsynaptic GluA2 410 
AMPA receptor (AMPAR) subunits showed that neither the punctate (synaptic 411 
AMPARs) nor the diffuse surface signal (dendritic/perisynaptic AMPARs) were 412 
significantly affected by aEPO superfusion (Figure 2A). Such lack of effect on 413 
postsynaptic AMPAR trafficking could hypothetically be attributed to a lack of 414 
expression of EpoR at neuronal dendrites. Immunocytochemistry studies on mature 415 
cultured hippocampal neurons showed that the EpoR mainly localized to the cell soma, 416 
but was also expressed, at lower levels, in the dendritic compartment (Figure 2B). 417 
Hence, a lack of expression of the EpoR should not account for the absence of effect on 418 




Prolonged exposure to EPO (pEPO) drives the homeostatic upscaling of excitatory and 421 
the downscaling of inhibitory spontaneous event, only if followed by a recovery period 422 
The results reported so far suggest that EPO acutely acts to inhibit synaptic 423 
transmission, mainly through presynaptic mechanisms. Next, we aimed to test whether a 424 
more prolonged exposure to EPO’s synaptic manipulation would be able to produce 425 
enduring, and perhaps more physiologically relevant, changes in synaptic transmission.  426 
Homeostatic forms of synaptic plasticity ultimately ensure long-term stability of 427 
neuronal function, by scaling synaptic-receptor currents up or down after prolonged 428 
activity decrease or increase, respectively (e.g., Turrigiano et al., 1998). Such synaptic 429 
scaling is usually measured as a change in quantal or miniature synaptic transmission 430 
(‘minis’), which accounts for the AP-independent fusion of synaptic vesicles at 431 
presynaptic terminals (e.g., Sutton et al., 2006; reviewed by Pozo and Goda, 2010). 432 
Therefore, we next investigated the effects of EPO on spontaneous miniature events.  433 
First, we tested the effect of aEPO (2.4 IU/ml; Figure 3C), which significantly 434 
decreased the frequency of miniature excitatory postsynaptic currents (mEPSCs) 435 
(baseline:0.42±0.10 Hz; after 40 min:0.26±0.08 Hz; n=7, p=0.0304, paired t-test; 436 
Figure 3D) and significantly increased the frequency of miniature inhibitory 437 
postsynaptic currents (mIPSC) (baseline:3.55±0.90 Hz; after 40 min:4.10±1.00 Hz; n=5, 438 
p=0.0088, paired t-test; Figure 3E). No significant effects were observed in 439 
mEPSC/mIPSC amplitude (Figure 3D-E), consistent with our previous thesis that EPO 440 
mainly operates through presynaptic mechanisms. Interestingly, these effects endured, 441 
even after prolonged (3h) exposure to EPO (pEPO, 2.4 IU/ml), followed by continuous 442 
EPO superfusion throughout the recording period (Figure 3F). Indeed, under these 443 
conditions, mEPSC frequency was found to be decreased (veh:0.20±0.02 Hz; 444 
EPO:0.12±0.02 Hz; n=5-8 per condition, p=0.0208, unpaired t-test; Figure 3G), and 445 
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mIPSC frequency was found to be increased (veh:1.67±0.36 Hz; EPO:3.41±0.53 Hz; 446 
n=9 per condition, p=0.0148, unpaired t-test; Figure 3H). 447 
Since changes in the spontaneous-related vesicle pool suffice to elicit homeostatic 448 
phenomena (Reese and Kavalali, 2015), we next tested if prolonged (3h) exposure to 449 
EPO (pEPO), followed by a recovery period (1h) to allow unmasking of the acute 450 
effects, could induce lasting homeostatic changes in neuronal transmission. Under these 451 
conditions, CA1 pyramidal cells displayed a higher frequency of mEPSCs 452 
(veh:0.08±0.01 Hz; EPO:0.29±0.08 Hz; n=11 per condition, p=0.0408, unpaired t-test 453 
with Welch’s correction; Figure 3J). Identical effects were observed when recording 454 
from hippocampal cultured neurons (Figure S3A), suggesting that the homeostatic 455 
changes induced by pEPO are inherently synaptic and do not require an intact circuitry.  456 
Even though quantal glutamate release at central synapses is assumed to mainly arise 457 
from AP-independent vesicle fusion, it can also result from AP-dependent activity (Ye 458 
et al., 2010). For this reason, we addressed the effects of pEPO upon spontaneous 459 
EPSCs (sEPSCs), which comprise responses to both types of release. No significant 460 
differences in sEPSC amplitude or decay were observed, although there was a trend for 461 
increased sEPSC frequency (Figure S3B-C). Since EPO does not affect spontaneous 462 
AP generation (Figure 1H), it is plausible to assume that spontaneous AP-driven 463 
events, if unaffected by EPO, might “blur” the scaling of co-recorded AP-independent 464 
events. 465 
GABAergic transmission was also affected by pEPO, when followed by a recovery 466 
period, through a downscaling in mIPSC frequency (veh:1.72±0.24 Hz; EPO:1.06±0.14 467 
Hz; n=6-7, p=0.0312, unpaired t-test; Figure 3K), which is reciprocal to the scaling 468 
effect of EPO on mEPSCs. 469 
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In addition to adjusting synaptic weights, homeostatic plasticity can also promote silent 470 
synapse formation (Arendt et al., 2013) or trigger changes in intrinsic membrane 471 
properties and neuronal excitability (Desai et al., 1999), to maintain stability in AP 472 
firing rates despite activity manipulation (Hengen et al., 2013; Keck et al., 2013).  In 473 
CA1 PCs exposed to pEPO (2.4 IU/ml, 3h), followed by a recovery period (1h), whole-474 
cell current-clamp recordings showed no significant differences in instantaneous AP 475 
firing frequency in response to soma depolarization (top parameter of fitted curves±s.e.: 476 
veh:34.89±1.50 Hz, EPO:37.68±2.27 Hz, p>0.05; slopes of fitted curves±s.e.: 477 
veh:0.0096±0.0018 Hz/pA, EPO:0.0094±0.0024 Hz/pA; n=15 per condition, p>0.05, 478 
sum-of-squares F-test; Figure 4A-C), nor in the maximum AP frequency, resting 479 
membrane potential (RMP), AP firing threshold or delay to first AP (Table 1). Hence, 480 
prolonged EPO does not seem to affect membrane excitability, nor the ability of the 481 
postsynaptic neuron to compute information under conditions of strong depolarization.  482 
Glutamatergic synapses that lack AMPARs and only contain NMDARs are functionally 483 
silent despite intact presynaptic glutamate release, due to the voltage-dependent 484 
magnesium blockade of NMDARs (Isaac et al., 1995). To detect silent synapses, 485 
voltage-clamped recordings from CA1 pyramidal cells were performed, and excitatory 486 
synaptic transmission was elicited by minimal electrical stimulation, which produced 487 
failures in 50% of trials (Figure 4D). Epochs of 50 trials were recorded at –60 mV and 488 
+40 mV for each cell, and the failure rate at these two holding potentials was calculated. 489 
The failure rate was comparable between the negative and the positive holding 490 
potentials both in vehicle- (–60 mV:42.67±3.65%; +40 mV:37.33±7.48%; n=9, 491 
p=0.4192, paired t-test) and in pEPO-treated slices (–60 mV:43.25±6.58%; +40 492 
mV:46.75±5.10%; n=8, p=0.6033, paired t-test; Figure 4E-G) for 3h, followed by a 493 
recovery period (1h). These data suggest that most SC-CA1 synapses are active in our 494 
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experimental conditions and that the number of silent synapses is not modified by 495 
prolonged exposure to EPO. 496 
 497 
Prolonged application of EPO (pEPO) decreases basal afferent-evoked synaptic 498 
transmission without modifying CA1 PC input-output function 499 
Thus far, we have shown that the inhibitory properties of EPO upon synaptic 500 
transmission suffice to induce long-lasting changes in synaptic weights, which are 501 
homeostatic, since they oppose the effects of aEPO. The increase in mEPSC frequency 502 
and the decrease in mIPSC frequency detected when pEPO was followed by a washout 503 
period (1h), are akin to the regulation of the excitatory-inhibitory balance previously 504 
described for TTX-based protocols of activity deprivation (AD) (Echegoyen et al., 505 
2007). The use of TTX-based paradigms to induce homeostatic plasticity is well 506 
established, as these have been extensively studied in recent years (reviewed, in detail, 507 
by Pozo and Goda, 2010). Therefore, they can serve as a good experimental standard, 508 
from which comparisons can be drawn, to further our understanding of the newly 509 
identified EPO paradigm. 510 
We have already identified two fundamental differences between these paradigms, 511 
since, contrarily to what we have shown for EPO, prolonged exposure to TTX (48-60h) 512 
was able to promote silent synapse formation in cultured hippocampal slices (Arendt et 513 
al., 2013) and to increase sensitivity of cultured cortical PCs to injected current by 514 
increasing voltage-dependent conductances (Desai et al., 1999). 515 
Notwithstanding, further comparisons need to be drawn to attain a fuller picture, 516 
particularly on the effects upon evoked transmission and hebbian plasticity phenomena. 517 
Our main experimental model (acute hippocampal slices) does not allow for such 518 
prolonged incubation periods with TTX. Sutton et al. (2006) showed that when TTX is 519 
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combined with blockade of postsynaptic NMDARs, synaptic scaling occurs an order of 520 
magnitude faster (3h). We previously showed that this combined bath-applied 521 
pharmacological AD protocol is able to upscale afferent-evoked excitatory transmission 522 
and to lower the threshold for associative, input-specific potentiation of synaptic 523 
strength (Félix-Oliveira et al., 2014). 524 
Thus, we next aimed to evaluate the effect of EPO on evoked synaptic transmission and 525 
to contrast it with that elicited by the AD protocol. To this end, we measured 526 
extracellularly recorded input-output (I/O) curves (each variable was calculated as 527 
detailed in Figure S4A). Consistent with previous results (Félix-Oliveira et al., 2014), 528 
field responses were increased in AD slices (top parameter of fitted curves±s.e.: 529 
veh:3.35±0.20 mV/ms, AD:4.66±0.36 mV/ms; n=8-9, p=0.0241, sum-of-square F-test; 530 
Figure 5A). In stark contrast, pEPO decreased the field responses to afferent 531 
stimulation (top parameter of fitted curves±s.e.: veh:3.35±0.20 mV/ms, EPO:2.68±0.14 532 
mV/ms; n=9 per condition, p=0.0161, sum-of-square F-test; Figure 5A). Simultaneous 533 
co-incubation with AD and pEPO (n=7) did not modify the I/O curve (vs. veh, 534 
p=0.3626), thus suggesting that these modulatory effects are opposite, additive and 535 
independent (Figure 5A). Importantly, these effects are unrelated to major changes in 536 
the recruitment of presynaptic neurons, as the presynaptic fiber volley amplitude 537 
(PFVA) was not significantly changed by EPO or AD (Figure S4B). When the fEPSP 538 
slope is plotted as a function of the PFVA, similar results are rendered, although the 539 
inhibitory effect of EPO (top parameter of fitted curves±s.e.: veh:3.75±0.65 mV/ms, 540 
EPO:2.91±0.43 mV/ms; n=9 per condition, Figure S4C) did not reach statistical 541 
significance (p=0.3747, sum-of-square F-test).  542 
We also measured the amplitude of the population spike (popspike) whenever the 543 
stimulus intensity was sufficient to elicit it (typically, above 220 μA stimulus intensity), 544 
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and plotted it against the corresponding fEPSP slope (Figure 5B). The popspike 545 
amplitude is a measure of CA1 pyramidal cell output, while the fEPSP slope evaluates 546 
the response to Schaffer collateral fibers depolarization induced by an electrical 547 
stimulus. Therefore, by correlating these two variables, we can assess how the 548 
hippocampal circuit itself is computing afferent stimulation (Rombo et al., 2015).  549 
Linear fittings of these values show no gross changes induced by either pEPO or AD 550 
(Figure 5B). More detailed analysis of the results pertaining high stimulus intensities 551 
shows a trend for change in popspike amplitude that closely reflects the changes in 552 
fEPSP slope (Figure S4D1). Therefore, we also calculated the quotient between the 553 
popspike amplitude and the fEPSP slope for all stimulus intensities and, accordingly, no 554 
significant changes were observed (right inset of Figure 5B). Also, subgroup analysis 555 
of the results according to stimulus intensity shows no differences between test 556 
conditions (Figure S4D2). Altogether, these data suggest that the CA1 pyramidal cell 557 
output to Schaffer collateral excitation is unaffected by either pEPO or AD. 558 
 559 
Activity deprivation and prolonged exposure to EPO prime hippocampal Long-Term 560 
Potentiation (LTP) through additive mechanisms 561 
Next, we evaluated how prolonged exposure to EPO affects the capacity of CA1 562 
neurons to undergo hebbian long-term potentiation (LTP). We elicited LTP at SC-CA1 563 
synapses by delivering a weak -burst protocol (see Materials and Methods). LTP 564 
magnitude following pEPO or AD treatment was significantly higher than in vehicle-565 
treated slices (veh:19.99±2.70%; vs pEPO:44.44±3.62%, p<0.01; vs AD:47.83±3.56%, 566 
p<0.01; n=9 per condition, one-way ANOVA with Sidak’s multiple comparisons test; 567 
Figure 6B-C). Furthermore, LTP elicited after co-incubation with pEPO and the AD 568 
protocol was significantly higher than in slices incubated with pEPO or AD alone 569 
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(AD+pEPO: 69.01±10.36%, p<0.05 for both comparisons; n=7-9, one-way ANOVA 570 
with Sidak’s multiple comparisons test; Figure 6C). As previously shown (Kamal et 571 
al., 2011), when EPO was applied only briefly before LTP induction (aEPO) it also 572 
significantly increased LTP magnitude (veh:19.99±2.70%, n=9; vs aEPO:43.59±4.66%, 573 
n=6, p<0.05, one-way ANOVA with Sidak’s multiple comparisons test; Figure 6D-E). 574 
However, aEPO did not increase LTP (or PTP) further after AD, yielding a significantly 575 
lower LTP magnitude, as compared to the LTP attained after co-incubation with AD 576 
and pEPO (AD+aEPO:45.33±4.31%, n=7; vs AD+pEPO:69.01±10.36%, n=7, p<0.05, 577 
one-way ANOVA with Sidak’s multiple comparisons test; Figure 6D-E). These results 578 
indicate that the mechanisms underlying acute EPO-mediated boost of LTP are different 579 
from the LTP priming-related changes that take place during the recovery period 580 
following prolonged exposure to EPO. 581 
Overall, these results also suggest that cumulative synaptic modifications are elicited by 582 
prolonged exposure to EPO or AD, rendering them more prone to -burst-induced LTP. 583 
One plausible explanation is that tuning of glutamatergic transmission by EPO would be 584 
different in an activity-deprived network. However, in this regard, we found that the 585 
effects of aEPO on mEPSCs and AMPA receptor trafficking were preserved after AD 586 
(see Figure S5A and Figure S5D), although the downregulation of fEPSPs was lost 587 
(see Figure S5B). Another possibility is that the synapses primed for LTP either in 588 
activity deprived conditions or after prolonged exposure to EPO, recruit distinct and 589 
independent mechanisms for LTP maintenance. Mature glutamatergic synapses are 590 
thought to express only calcium-impermeable (CI), GluA2-containing AMPARs. 591 
Contribution of calcium-permeable (CP), GluA2-lacking AMPAR to LTP is more 592 
controversial. The current view is that CP-AMPARs are needed for -burst LTP 593 
induction, but not for tetanus-induced LTP, nor for -burst LTP maintenance (Plant et 594 
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al., 2006; see also Adesnik and Nicoll, 2007). To evaluate if CP-AMPAR recruitment 595 
could contribute to the higher LTP magnitudes attained after pEPO or after AD, we 596 
delivered the same weak -burst protocol to two independent pathways and added the 597 
specific CP-AMPAR extracellular blocker, NASPM (20 μM; Blaschke et al., 1993), to 598 
the superfusion solution, 20 min after LTP induction in the second pathway. NASPM 599 
significantly decreased the magnitude of LTP primed by pEPO, but not by AD 600 
(pEPO+NASPM:30.90±2.49% vs AD+NASPM:52.56±4.80%, p<0.01; 601 
pEPO:45.22±4.33% vs AD:49.71±3.10%, p>0.05; n=6-7, one-way ANOVA with 602 
Bonferroni’s correction; Figure 7). These data suggest that, unlike the mechanisms 603 
engaged by activity deprivation, LTP primed by prolonged exposure to EPO requires 604 
CP-AMPAR for LTP maintenance stage.   605 




Research over the last 20 years has highlighted roles for EPO far beyond erythropoiesis 608 
(Fond et al., 2012). Although data from several cohorts uphold the inkling that EPO 609 
acts as a cognitive enhancer, its actions on synaptic function and plasticity have 610 
remained elusive. 611 
The work herein described is the first to show that EPO is able to elicit homeostatic 612 
plasticity phenomena (Supplementary Table 1). In this regard, our results revealed that 613 
acute EPO acts as an inhibitor of excitatory synaptic transmission, while prolonged 614 
exposure to EPO (if followed by a recovery period) produces opposite changes, i.e. an 615 
upregulation of spontaneous miniature excitatory events. Homeostatic scaling was first 616 
described as a slow compensatory upscaling of synaptic strength secondary to loss of 617 
AP-driven neurotransmission by long-term (24h) exposure to TTX (Turrigiano et al., 618 
1998). Subsequent work showed that when TTX was combined with blockade of 619 
NMDAR-mediated responses to stochastic quantal glutamate release, homeostatic 620 
adjustment of spontaneous transmission occurred an order of magnitude faster (3h) 621 
(Sutton et al., 2006). Here, for the first time, we describe a paradigm that induces 622 
similar homeostatic changes in spontaneous transmission, while leaving AP-driven 623 
events and the number of silent synapses intact. These homeostatic changes require, 624 
nonetheless, a recovery period (1h), in EPO-free aCSF. Such dependence on a 625 
reactivation stage has been previously noted for the homeostatic changes in excitatory 626 
transmission induced by TTX (Gerkin et al., 2013). 627 
While evaluating spontaneous (AP-dependent and independent) synaptic activity in 628 
mice chronically treated with EPO, Adamcio et al., (2008) reported an increase in 629 
inhibitory and a decrease in excitatory transmission, which is in apparent conflict with 630 
our observations on mEPSC, mIPSC and sEPSC scaling. This discrepancy may be due 631 
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to species- and/or age-related differences in EpoR expression, which progressively 632 
decreases postnatally (Sanchez et al., 2009). Furthermore, chronic EPO administration 633 
in vivo (Adamcio et al., 2008) may lead to receptor desensitization and/or affect 634 
receptor coupling to downstream transduction pathways. 635 
When studying afferent-evoked synaptic transmission, we observed that, unlike AD 636 
(Félix-Oliveira et al., 2014), not only does prolonged EPO fail to potentiate, as it 637 
decreases the input-output relationship. This inhibition could reflect the reduction in the 638 
readily releasable pool size shown to occur after prolonged exposure of autaptic 639 
neuronal cultures to a low concentration of EPO (Adamcio et al., 2008). Alternatively, 640 
it can be directly linked to the upscaling in spontaneous transmission. Indeed, recent 641 
studies challenge the classical association between the fusion rates of spontaneous- and 642 
activity-dedicated vesicles, by showing that these two forms of release may be 643 
independent (Melom et al., 2013) or may even correlate inversely (Peled et al., 2014).  644 
Intriguingly, EPO attains lasting and opposite modifications of both evoked and 645 
spontaneous transmission, with only the latter corresponding to a compensatory 646 
homeostatic upscaling. In contrast, AD homeostatically upregulates both spontaneous 647 
and electrically-evoked transmission (Félix-Oliveira et al., 2014). This discrepancy 648 
likely relates to a fundamental difference between both paradigms. EPO mainly silences 649 
stochastic glutamatergic inputs onto their postsynaptic contacts, while not affecting AP 650 
generation. Hence, it affords a more selective modulation of the spontaneous release 651 
(not AP-driven) vesicle pool. In contrast, the AD paradigm (Sutton et al., 2006) attains 652 
a much stronger but less selective inhibition of excitatory transmission. Therefore, while 653 
our data support that AP blockade is not an absolute requirement for the rapid scaling of 654 
miniature transmission, we also demonstrate that the consequences for synaptic function 655 
are not independent of AP blockade. Another advantage in having contrasted EPO with 656 
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the AD paradigm is that it allowed us to address how EPO affects synaptic transmission 657 
and plasticity of activity deprived neurons. Such data is timely, given that EPO is 658 
currently considered a potential therapeutic option for patients with ischemic stroke 659 
(e.g., Cramer et al., 2014; Ehrenreich et al, 2009). Indeed, the present experimental 660 
conditions may resemble those of neurons that remain viable after a stroke event, albeit 661 
suffering from activity deprivation due to loss of input from ischemic afferent neurons.  662 
Overall, our data also support the emerging view that spontaneous and activity-663 
dependent pools of vesicles are spatially and functionally segregated and may, thus, be 664 
independently regulated (Kavalali, 2015). Our results further suggest that EPO acts 665 
mainly through presynaptic targets, putatively through one or more of the proteins that 666 
comprise the vesicle release machinery preferentially devoted to spontaneous release 667 
(e.g., Chung et al., 2010). In this regard, presynaptic-derived forms of homeostatic 668 
plasticity have been previously described (e.g., Murthy et al., 2001). 669 
Despite their differences, both prolonged EPO and AD prime plasticity at the 670 
hippocampus. LTP has been reported to increase after acute superfusion with EPO 671 
(Kamal et al., 2011) and following chronic EPO injections (Adamcio et al., 2008). 672 
However, the underlying molecular mechanisms in both time frames seem to be 673 
different, as we herein show that, unlike prolonged EPO, acute EPO-driven 674 
enhancement of LTP is not cumulative with previous AD. On the one hand, LTP 675 
requires intracellular calcium to rise in specific subcellular compartments beyond a 676 
critical threshold (Citri and Malenka, 2008) and EPO can acutely activate calcium 677 
channels, rapidly increasing intracellular Ca2+ (Koshimura et al., 1999). On the other 678 
hand, we now show that prolonged EPO causes a homeostatic response in spontaneous 679 
transmitter release, which, in and of itself, suffices to elicit postsynaptic plasticity 680 
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(Nosyreva et al., 2013) and has also been shown to mediate the rapid antidepressant 681 
action of ketamine (Autry et al., 2011; Nosyreva et al., 2013). 682 
In keeping with the idea that prolonged EPO and AD do not engage the same 683 
mechanisms to boost plasticity is the finding that, when co-applied, EPO and AD have 684 
an additive influence over LTP. Moreover, pEPO- and AD-primed LTP are maintained 685 
through different processes. Vehicle-treated and AD-primed LTPs are not affected by 686 
superfusion with a specific CP-AMPAR inhibitor during their consolidation stage, 687 
supporting prior evidence that these receptors do not contribute for LTP maintenance 688 
(Plant et al., 2006). In contrast, prior treatment with pEPO leads to an enhanced LTP 689 
that is sensitive to CP-AMPAR blockade. Although GluA2-lacking CP-AMPA 690 
receptors are virtually excluded from adult synapses (Henley and Wilkinson, 2016), 691 
integration of relevant stimuli can recruit them from extrasynaptic pools into the 692 
synaptic compartment (Oh et al., 2006), where a proportionally small increase in CP-693 
AMPARs (~5%) is enough to afford the facilitation of synaptic efficiency that is 694 
obtained in -burst LTP (Guire et al., 2008). Our results thus provide the first evidence 695 
that mature synapses, under specific circumstances, may recruit CP-AMPARs beyond 696 
the induction stage and into LTP maintenance. Future work will elucidate if other 697 
paradigms with similar consequences for presynaptic release can engage CP-AMPAR-698 
dependent mechanisms for LTP consolidation or, alternatively, if this is an effect 699 
specifically elicited by EPO. However, we cannot exclude that other, concurrent 700 
mechanisms also underlie the cumulative effect of prolonged EPO and AD on LTP 701 
magnitude.  Indeed, long term (60h) incubation with TTX was shown to enhance LTP 702 
by inducing silent synapse formation (Arendt et al., 2013), contrarily to what our 703 
results suggest for EPO (Figure 4D-G). 704 
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In conclusion, our data show that EPO acts predominantly as an excitatory transmission 705 
inhibitor, acutely downtuning spontaneous and, to a lesser extent, afferent-evoked 706 
neurotransmission. Consistently, prolonged exposure to EPO, when followed by a 707 
recovery period, selectively elicits homeostatic changes in spontaneous but not in 708 
evoked transmission, while leaving neuronal intrinsic properties and the proportion of 709 
silent synapses intact. EPO also primes synapses to undergo associative plasticity, 710 
recruiting a non-canonical CP-AMPAR-dependent mechanism for LTP maintenance. 711 
Collectively, our results represent a significant advance toward the understanding of the 712 
synaptic basis for EPO’s pro-cognitive effects and challenge some currently prevailing 713 
views on fundamental principles of synaptic transmission and plasticity.  714 
  715 
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Table 1. Measures of intrinsic excitability of hippocampal CA1 pyramidal cells. 
 Vehicle (n = 15) pEPO (n=15) p* 
Resting Membrane 
Potential (Vm) (mV) 
59.34  1.22 58.30  1.25 0.5576 
AP firing threshold 
( Vm  Vt) 
7.53  1.51 6.18  1.82 0.5356 
Delay to first AP 
(ms) 
84.19  7.89 74.92  6.70 0.3812 
t (AP1 to AP2) (ms) 88.46  17.42 102.70  25.35 0.6442 
Maximum AP firing 
frequency (Hz) 
33.87  1.13 36.27  1.76 0.2599 
* Unpaired t-test 956 
  957 
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Figure Captions 958 
 959 
Figure 1. Acute EPO (aEPO) presynaptically downregulates afferent-evoked 960 
transmission at SC-CA1 synapses, with no concurrent changes in postsynaptic 961 
excitability. 962 
(A) Schematic representation of orthodromic fEPSP recordings at SC-CA1 synapses. 963 
(B) Panel (B1) represents the time course of averaged normalized changes in fEPSP 964 
slope induced by superfusion with vehicle or EPO (aEPO, 2.4 IU/ml) (n=10 per 965 
condition). Panel (B2) shows the time course of average normalized changes in fEPSP 966 
slope in slices superfused with aEPO (2.4 IU/ml) in the presence of a tyrosine kinase 967 
inhibitor, k252a (200 mM), which was applied 30 min before EPO (n=5); control data 968 
from slices exposed only to k252a (200 mM) for the same amount of time is also shown 969 
(n=5). Data represented as mean ± s.e.m. Top insets: tracings obtained from 970 
representative experiments, as indicated, before (black) and 60 min after (gray) 971 
vehicle/aEPO superfusion. 972 
(C) Histogram shows percentage changes in the average slope of the fEPSP, for the 973 
recordings in (B). Data represented as mean ± s.e.m. ****p<0.0001, as compared to 974 
vehicle; ρρ p<0.01, ρρρ p<0.001, as compared to aEPO perfusion alone (one-way 975 
ANOVA with Tukey’s multiple comparisons test). 976 
(D) PPF values for each individual experiment, with a line connecting averaged PPF 977 
values at baseline and after 40 min, in slices perfused with vehicle (Veh) (n=5, left 978 
panel) or with aEPO (2.4 IU/ml) (n=5, right panel). Histograms depict mean ± s.e.m. for 979 
each set of values. ** p<0.01, n.s. not significant (paired t-test) Right inset: tracings 980 
from representative experiments, as indicated, before (black) and 40 min after (gray) 981 
vehicle/aEPO application. 982 
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(E) Schematic representation of antidromic population spike (popspike) recordings at 983 
the pyramidal cell layer.  984 
(F) Time course of averaged normalized changes in popspike amplitude induced by 985 
superfusion with vehicle (n=5) or aEPO (2.4 IU/ml, n=6). Data represented as mean ± 986 
s.e.m. Top insets: tracings obtained from representative experiments, as indicated, 987 
before (black) and 60 min after (gray) vehicle/aEPO superfusion. 988 
(G) Schematic representation of intracellular recordings in current-clamp (CC) mode 989 
from CA1 pyramidal cells (PC). 990 
(H) Box and whiskers depicting the distributions of averaged AP firing frequencies 991 
recorded in current-clamp mode, during superfusion with either vehicle (Veh) (n=9) or 992 
aEPO (2.4 IU/ml) (n=6). n.s. not significant (Mann-Whitney test). Right inset: 993 
representative tracings. 994 
 995 
Figure 2. Acute EPO (aEPO) superfusion does not affect AMPAR trafficking at 996 
dendritic spines. 997 
(A) The left panels in (A1) and (A2) depict the time courses of normalized changes in 998 
SEP-GluA2 fluorescence of punctate and diffuse surface GluA2 signal, respectively 999 
(n=3-4 ROI per neuron; 6 neurons DIC 17-24, from 2 independent cultures). The right 1000 
panels in (A1) and (A2) depict the averaged fluorescence calculated at baseline and in 1001 
the last 9 min of aEPO perfusion, with a line connecting averaged values from the same 1002 
experiment (n=6). In this set of experiments, EPO was applied for only 12 min to 1003 
minimize GluA2 fluorescence bleaching. Data represented as mean ± s.e.m. n.s. not 1004 
significant (paired t-test). The representative dendrite in (A3) illustrates where the 1005 
punctate (Spine, Sp) and diffuse (Dif) signals were measured. 1006 
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(B-C) Representative images of cultured hippocampal neurons at either DIC 15 (B) or 1007 
DIC 21 (C) stained for the dendritic marker MAP2 (red) (B1, C1) and the EpoR protein 1008 
(green) (B2, C2). The panels below (B) and (C) depict virtual images of the neurons in 1009 
the main panels, generated by the ImageJ software, to exemplify the quantification of 1010 
the mean gray values. Through the identification of the neuronal area on the MAP2 1011 
channel (white painted area on the left virtual image from the MAP2 channel) and cell 1012 
body region (red polygonal line on the right virtual image from the MAP2 channel), the 1013 
two ROIs (cell body area and processes area) were generated to quantify the EpoR 1014 
signal intensity in the cell body (white painted area on the left virtual image from the 1015 
EpoR channel) and in dendrites (white painted area on the right virtual image from the 1016 
EpoR channel). Scale bar = 30m.  1017 
(D) Histogram depicting the average mean gray values of EpoR protein signal intensity 1018 
in the cell body (Soma) and in the dendrites (Dend), either at DIC 15 or DIC 21, as 1019 
indicated below each bar. Data are expressed as mean ± s.e.m. from 60 neurons, taken 1020 
from 2 independent cultures (30 neurons analyzed per culture) ***p<0.0001 (paired t-1021 
test). 1022 
 1023 
Figure 3. Prolonged EPO (pEPO) drives homeostatic changes in miniature 1024 
excitatory and inhibitory synaptic events, opposite to its acute effects (aEPO), only 1025 
if exposure is followed by a recovery period. 1026 
(A-B) Schematic representation of mEPSC (A) and mIPSC recordings from CA1 1027 
pyramidal cells (PC). IN. Interneurons. VC. Voltage-clamp. 1028 
(D-E) Panels in (D) and (E) depict the values of frequency (left panels), amplitude 1029 
(central panels) and decay (right panels) of mEPSC (D) and mIPSC (E) events, which 1030 
are plotted with a line connecting values at baseline and after 40 min superfusion with 1031 
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aEPO (2.4 IU/ml) (n=7 for mEPSC recordings; n=5 for mIPSC recordings). Histograms 1032 
represent mean ± s.e.m. for each dataset. * p<0.05, ** p<0.01, n.s. not significant 1033 
(paired t-test). Top insets: representative mEPSC and mIPSC tracings, at baseline and 1034 
after aEPO (2.4 IU/mL) superfusion, are shown in panels (D) and (E), respectively.  1035 
(G-H) Histograms depict the frequency (left panels), amplitude (central panels) and 1036 
decay (right panels) of mEPSC (G, n=5-8 per condition) and mIPSC (H, n=9 per 1037 
condition) events recorded from CA1 PCs of hippocampal slices incubated for 3h with 1038 
either vehicle (black) or pEPO (2.4 IU/ml, gray) and thereafter continuously superfused 1039 
with EPO (2.4 IU/ml), in order to avoid recovery. Data represented as mean ± s.e.m. * 1040 
p<0.05, n.s. not significant (unpaired t-test). Top insets: representative mEPSC (G) and 1041 
mIPSC (H) tracings, for each condition.  1042 
(J-K) Histograms depict the frequency (left panels), amplitude (central panels) and 1043 
decay (right panels) of mEPSC (J, n=11 per condition) and mIPSC (L, n=6-7 per 1044 
condition) events recorded from CA1 PCs of hippocampal slices incubated for 3h with 1045 
either vehicle (black) or pEPO (2.4 IU/ml, gray), followed by a 1h recovery period. 1046 
Data represented as mean ± s.e.m. * p<0.05, n.s. not significant (unpaired t-test with 1047 
Welch's correction for mEPSC data; unpaired t-test mIPSC data). Top insets: 1048 
representative mEPSC (J) and mIPSC (K) tracings, for each condition.  1049 
Schematic representations of the experimental designs for acute EPO application (C) 1050 
and prolonged EPO exposure [either with (I) or without (F) a recovery/washout (Wsh) 1051 






Figure 4. Prolonged EPO (pEPO) does not affect postsynaptic membrane 1056 
excitability, nor the proportion of silent synapses. 1057 
(A) Schematic representation of intracellular recordings in current-clamp (CC) mode 1058 
from CA1 pyramidal cells (PC). 1059 
(B) Instantaneous AP firing frequency is plotted as a function of injected current 1060 
for CA1 PCs from hippocampal slices treated with pEPO (2.4 IU/ml) or vehicle for 3h 1061 
(n=15 per condition), followed by a 1h recovery period. Data represented as mean ± 1062 
s.e.m. with non-linear fittings. 1063 
(C) Representative AP firing pattern (left) and maximum AP firing (right) tracings are 1064 
shown for each condition (vehicle-treated in black; pEPO-treated in gray). 1065 
(D) Schematic representation of intracellular recordings from CA1 pyramidal cells (PC) 1066 
of electrically evoked AMPA- and NMDA-mediated responses. 1067 
(E) Panel depicts the quantification of failure rate of evoked responses for vehicle- 1068 
(n=9) and pEPO-treated (n=8) cells. Individual experiments are plotted with a line 1069 
connecting failure rate values at –60 and +40 mV holding potentials. Histograms 1070 
represent mean ± s.e.m. for each dataset. Failure rate is calculated from 50 sweeps per 1071 
cell. n.s. not significant (paired t-test) 1072 
(F-G) Example tracings and scatter plot of evoked EPSCs from one vehicle- (F) and 1073 
one pEPO-treated (G) neuron at –60 and +40 mV holding potentials. Failed events were 1074 
assigned an amplitude of zero for ease of visualization. 1075 
 1076 
Figure 5. Prolonged EPO (pEPO) downregulates afferent-evoked synaptic 1077 
transmission. 1078 
(A) Input/Output curves from vehicle-, AD-, pEPO- and both AD/pEPO-treated slices 1079 
(n=7-9 per condition), where the fEPSP slope is plotted as a function of stimulus 1080 
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intensity. Data represented as mean ± s.e.m. with non-linear fittings. Right inset: 1081 
histogram depicting the top parameter of the fitted curves in (A) for each condition ± 1082 
standard error. *p<0.05 (sum-of-squares F-test). Bottom inset: representative tracings 1083 
are shown for each condition depicting evoked responses to 180, 240 and 300 μA 1084 
stimulations. 1085 
(B) Population spike amplitude is plotted as a function of the fEPSP slope; data from all 1086 
the field responses in which the population spike was elicited were included. The lines 1087 
represent linear fittings (n=7-9 per condition). Right inset: histogram depicting the 1088 
popspike amplitude / fEPSP slope ratio. Data represented as mean ± s.e.m. n.s. not 1089 
significant (one-way ANOVA with Bonferroni’s correction). 1090 
 1091 
Figure 6. Prolonged EPO (pEPO) and AD cumulatively boost hippocampal Long-1092 
Term Potentiation (LTP). 1093 
(A) Schematic representation of fEPSP recordings at SC-CA1 synapses (A1). The weak 1094 
θ-burst LTP-inducing protocol (A2) was delivered by S1. 1095 
(B-D) Experimental designs are respectively shown in (B1), (C1) and (D1). Panels (B2) 1096 
and (C2) depict the time courses of averaged normalized changes in fEPSP slope after 1097 
delivery (arrow) of a weak -burst (1x4x4) to vehicle-treated or AD-treated 1098 
hippocampal slices (B2, n=9 per condition), and to pEPO-treated or AD+pEPO-treated 1099 
slices (C2, n=7-9 per condition). Panel (D2) depicts the time course of averaged 1100 
normalized changes in fEPSP slope after delivery (arrow) of a weak -burst (1x4x4) to 1101 
vehicle-treated and AD-treated slices (n=6-7 per condition), but where aEPO (2.4 1102 
IU/ml) was only present in the superfusion solution, at least 60 min before LTP 1103 
induction and was kept for the 60 min subsequent to LTP induction. Data represented as 1104 
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mean ± s.e.m. Right insets: representative tracings, as indicated, before (thin line) and 1105 
60 min after (thicker line) -burst delivery. 1106 
(E) Histograms depict averaged LTP (E1) and PTP magnitudes (E2), for the recordings 1107 
shown in (B-D). Data represented as mean ± s.e.m. *p<0.05, **p<0.01, ****p<0.0001, 1108 
as compared to vehicle; ρ p<0.05, as compared to AD+pEPO (one-way ANOVA with 1109 
Sidak’s multiple comparisons test). 1110 
 1111 
Figure 7. Prolonged EPO (pEPO) recruits calcium-permeable AMPA receptors 1112 
(CP-AMPAR) for LTP maintenance. 1113 
(A) Schematic representation of fEPSP recordings at SC-CA1 synapses (A1). The weak 1114 
θ-burst LTP-inducing protocol was delivered to two independent pathways (S1 and S2). 1115 
The experimental design is shown in (A2). 1116 
(B) The top panels represent the time course of changes in fEPSP slope after delivery 1117 
(arrow) of a weak -burst (1x4x4) to both pathways of vehicle- (B1), pEPO- (B2) and 1118 
AD-treated (B3) slices (n=6-7 per condition). NASPM (20 μM) superfusion began 20 1119 
min after LTP induction in the 2nd pathway (full circles), which was induced at least 60 1120 
min following LTP induction in the 1st pathway (open circles). The bottom panels show 1121 
the time course of averaged normalized changes in fEPSP slope in the 2nd pathway 1122 
during LTP induction in the 1st pathway. Data represented as mean ± s.e.m. 1123 
(C) Histogram depicting averaged LTP magnitudes, for the recordings in (B) (n=6-7 per 1124 
condition). Data represented as mean ± s.e.m. **p<0.01, ***p<0.001, as compared to 1125 
vehicle; φφ p<0.01, φφφ p<0.001, as compared to AD (one-way ANOVA with 1126 
Bonferroni’s correction). 1127 
 1128 
 1129 
